AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36658380 — intervention group
Group type: COMPARATOR
Intervention: Decrease heart rate variability (HRV) biofeedback (Osc-)
Number of subjects: 165
Study 36658425 — intervention group
Group type: EXPERIMENTAL
Intervention: IACS-010759
Number of subjects: 40
Study 36658425 — intervention group
Group type: EXPERIMENTAL
Intervention: IACS-010759 with coadministration of a histone deacetylase 6 inhibitor
Number of subjects: 40
Study 36658543 — intervention group
Group type: EXPERIMENTAL
Intervention: Procalcitonin antibiotic prescribing guideline adherence
Number of subjects: 1656
Study 36658543 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1656
Study 36658543 — intervention group
Group type: EXPERIMENTAL
Intervention: Procalcitonin antibiotic prescribing guideline adherence after discharge
Number of subjects: 1656
Study 36658543 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% adherence in the emergency department
Number of subjects: 1656
Study 36658543 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics prescribed in the emergency department despite low procalcitonin
Number of subjects: 1656
Study 36658571 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking with light stripes
Number of subjects: 15
Study 36658571 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking to metronome beats
Number of subjects: 15
Study 36658571 — intervention group
Group type: COMPARATOR
Intervention: Baseline (with no cues)
Number of subjects: 15
Study 36658607 — intervention group
Group type: EXPERIMENTAL
Intervention: Spa therapy associated with self-management workshops
Number of subjects: 250
Study 36658607 — intervention group
Group type: COMPARATOR
Intervention: Spa therapy alone
Number of subjects: 250
Study 36658611 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth multicomponent training program plus health education program (MTHE)
Number of subjects: 0
Study 36658611 — intervention group
Group type: COMPARATOR
Intervention: Health education program alone (HE)
Number of subjects: 0
Study 36658611 — intervention group
Group type: EXPERIMENTAL
Intervention: MTHE
Number of subjects: 0
Study 36658635 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity exercise
Number of subjects: 351
Study 36658635 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-moderate intensity exercise
Number of subjects: 351
Study 36658653 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercises supervised by a physiotherapist (inspiratory muscle training, aerobic exercises, and strength exercises) for a minimum of 6 sessions in the pre-operative period, complemented with unsupervised exercise sessions.
Number of subjects: 160
Study 36658653 — intervention group
Group type: COMPARATOR
Intervention: Usual care with the addition of advice on health-enhancing physical activity.
Number of subjects: 160
Study 36658663 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy (MBCT) in addition to treatment as usual (TAU)
Number of subjects: 0
Study 36658663 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU) only
Number of subjects: 0
Study 36658663 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy (MBCT)
Number of subjects: 0
Study 36659633 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine 30 mg three times a day
Number of subjects: 654
Study 36659633 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 654
Study 36659832 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored adjuvant treatment based on WHO-endorsed molecular classification
Number of subjects: 590
Study 36659832 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (not explicitly mentioned in the abstract)
Number of subjects: 590
Study 36660190 — intervention group
Group type: EXPERIMENTAL
Intervention: M89PF
Number of subjects: 0
Study 36660190 — intervention group
Group type: COMPARATOR
Intervention: Usual skin care
Number of subjects: 0
Study 36660886 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose combination (FDC) therapy
Number of subjects: 4427
Study 36660886 — intervention group
Group type: COMPARATOR
Intervention: Free pill combination therapy
Number of subjects: 4427
Study 36661092 — intervention group
Group type: EXPERIMENTAL
Intervention: Insomnia Severity Index (ISI)
Number of subjects: 72
Study 36661240 — intervention group
Group type: COMPARATOR
Intervention: Low-dose SAB-185 (3840 units/kg)
Number of subjects: 428
Study 36661240 — intervention group
Group type: COMPARATOR
Intervention: High-dose SAB-185 (10240 units/kg)
Number of subjects: 428
Study 36661240 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 428
Study 36661315 — intervention group
Group type: EXPERIMENTAL
Intervention: Darinaparsin (300 mg/m2 over 1 hour, once daily for 5 consecutive days, per 21-day cycle)
Number of subjects: 65
Study 36661315 — intervention group
Group type: EXPERIMENTAL
Intervention: Darinaparsin
Number of subjects: 65
Study 36661328 — intervention group
Group type: EXPERIMENTAL
Intervention: AWOT (Adaptively Weighted Joint Test)
Number of subjects: 0
Study 36661328 — intervention group
Group type: EXPERIMENTAL
Intervention: CWOT (Cauchy Weighted Joint Test)
Number of subjects: 0
Study 36661328 — intervention group
Group type: EXPERIMENTAL
Intervention: AWOT and CWOT applied to PGx GWAS from Bezlotoxumab Clostridium difficile MODIFY I/II Phase 3 trials
Number of subjects: 0
Study 36661416 — intervention group
Group type: EXPERIMENTAL
Intervention: Compliant initial transfusion (hemoglobin < 7 g/dL)
Number of subjects: 687
Study 36661449 — intervention group
Group type: EXPERIMENTAL
Intervention: Unmet nonmedication needs (UDNs) for durable medical equipment (DME)
Number of subjects: 195
Study 36661449 — intervention group
Group type: EXPERIMENTAL
Intervention: Unmet nonmedication needs (UDNs) for home health services (HHS)
Number of subjects: 195
Study 36661449 — intervention group
Group type: EXPERIMENTAL
Intervention: Unmet nonmedication needs (UDNs) for follow-up medical appointments (FUAs)
Number of subjects: 195
Study 36661449 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall unmet nonmedication needs (UDNs)
Number of subjects: 195
Study 36661449 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater than median level of unmet needs
Number of subjects: 195
Study 36661449 — intervention group
Group type: COMPARATOR
Intervention: Composite outcome of 90-day readmission or death
Number of subjects: 195
Study 36661670 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy (RT)
Number of subjects: 165
Study 36662130 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum Lp(a) concentrations (median 19.9 (8.4-76.4) mg/dL)
Number of subjects: 97
Study 36662282 — intervention group
Group type: EXPERIMENTAL
Intervention: Real rTMS
Number of subjects: 40
Study 36662282 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 40
Study 36662344 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepolizumab 100 mg subcutaneously every 4 weeks
Number of subjects: 407
Study 36662344 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 407
Study 36662544 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized notifications
Number of subjects: 655
Study 36662544 — intervention group
Group type: COMPARATOR
Intervention: Standard notifications
Number of subjects: 655
Study 36662561 — intervention group
Group type: EXPERIMENTAL
Intervention: Empowered Survivor (ES)
Number of subjects: 600
Study 36662561 — intervention group
Group type: COMPARATOR
Intervention: Springboard Beyond Cancer
Number of subjects: 600
Study 36662568 — intervention group
Group type: EXPERIMENTAL
Intervention: PEAR-002b
Number of subjects: 10
Study 36662589 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-Loop Technology
Number of subjects: 0
Study 36662635 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg
Number of subjects: 4304
Study 36662635 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4304
Study 36662723 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir-based first-line antiretroviral treatment (ART)
Number of subjects: 61
Study 36662819 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (genomically-directed combination therapies)
Number of subjects: 0
Study 36662819 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of targeted agents and combinations of targeted therapy with chemotherapy
Number of subjects: 0
Study 36662819 — intervention group
Group type: EXPERIMENTAL
Intervention: Histology-specific and histology-agnostic arms
Number of subjects: 0
Study 36662819 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-arm and randomized designs
Number of subjects: 0
Study 36662821 — intervention group
Group type: EXPERIMENTAL
Intervention: Social media-based health education program (16 minutes video on PNC, reminders to view weekly for a month)
Number of subjects: 229
Study 36662821 — intervention group
Group type: EXPERIMENTAL
Intervention: Social media-based health education program
Number of subjects: 229
Study 36662821 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 229
Study 36662869 — intervention group
Group type: EXPERIMENTAL
Intervention: Riluzole (recommended daily oral dose for two weeks)
Number of subjects: 90
Study 36662869 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 36662869 — intervention group
Group type: EXPERIMENTAL
Intervention: Riluzole
Number of subjects: 90
Study 36662903 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide (375 mg/day, n = 34)
Number of subjects: 59
Study 36662903 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 25)
Number of subjects: 59
Study 36669140 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval-compressed chemotherapy with ganitumab (VDC/IE with ganitumab at cycle starts and as monotherapy once every 3 weeks for 6 months after conventional therapy)
Number of subjects: 298
Study 36669140 — intervention group
Group type: COMPARATOR
Intervention: Standard arm (interval-compressed vincristine/doxorubicin/cyclophosphamide alternating once every 2 weeks with ifosfamide/etoposide = VDC/IE)
Number of subjects: 298
Study 36669143 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (anti-PD-1 antibody) + Nintedanib (pan-antiangiogenic tyrosine kinase inhibitor)
Number of subjects: 30
Study 36669143 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab + Nintedanib
Number of subjects: 30
Study 36669146 — intervention group
Group type: EXPERIMENTAL
Intervention: Milademetan (260 mg once daily on days 1-3 and 15-17 every 28 days)
Number of subjects: 107
Study 36669146 — intervention group
Group type: EXPERIMENTAL
Intervention: Milademetan (intermittent schedule)
Number of subjects: 107
Study 36669146 — intervention group
Group type: EXPERIMENTAL
Intervention: Milademetan (overall in dedifferentiated liposarcomas)
Number of subjects: 107
Study 36669146 — intervention group
Group type: EXPERIMENTAL
Intervention: Milademetan (overall)
Number of subjects: 107
Study 36669148 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexrazoxane
Number of subjects: 195
Study 36669148 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin
Number of subjects: 195
Study 36669360 — intervention group
Group type: EXPERIMENTAL
Intervention: Daratumumab plus tapered steroids
Number of subjects: 2
Study 36669360 — intervention group
Group type: COMPARATOR
Intervention: Rituximab (implied as a previous treatment)
Number of subjects: 2
Study 36669663 — intervention group
Group type: EXPERIMENTAL
Intervention: Active HEPA air cleaners
Number of subjects: 0
Study 36669663 — intervention group
Group type: COMPARATOR
Intervention: Placebo HEPA air cleaners
Number of subjects: 0
Study 36669727 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic gait training
Number of subjects: 0
Study 36669727 — intervention group
Group type: COMPARATOR
Intervention: Functional clinical therapy
Number of subjects: 0
Study 36669772 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG-rhGH 0.2 mg/kg/wk (high-dose)
Number of subjects: 1170
Study 36669772 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG-rhGH 0.1 to <0.2 mg/kg/wk (low-dose)
Number of subjects: 1170
Study 36669772 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG-rhGH (both doses)
Number of subjects: 1170
Study 36669791 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous V937 (dose-escalation cohorts)
Number of subjects: 103
Study 36669791 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous V937 + pembrolizumab 200 mg every 3 weeks
Number of subjects: 103
Study 36669791 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous V937
Number of subjects: 103
Study 36669839 — intervention group
Group type: EXPERIMENTAL
Intervention: TeamSTEPPS training program
Number of subjects: 0
Study 36669845 — intervention group
Group type: EXPERIMENTAL
Intervention: ConquerFear-HK intervention
Number of subjects: 174
Study 36669845 — intervention group
Group type: COMPARATOR
Intervention: BasicCancerCare control
Number of subjects: 174
Study 36669847 — intervention group
Group type: EXPERIMENTAL
Intervention: PREP Plus (PREP and GRASP)
Number of subjects: 60
Study 36669847 — intervention group
Group type: COMPARATOR
Intervention: PREP alone
Number of subjects: 60
Study 36669872 — intervention group
Group type: EXPERIMENTAL
Intervention: Migalastat treatment for 18 months
Number of subjects: 16
Study 36669936 — intervention group
Group type: EXPERIMENTAL
Intervention: C-PAP/PSV
Number of subjects: 200
Study 36669936 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive mechanical ventilation
Number of subjects: 200
Study 36669936 — intervention group
Group type: COMPARATOR
Intervention: High Flow Nasal Oxygen (HFNO)
Number of subjects: 200
Study 36669936 — intervention group
Group type: EXPERIMENTAL
Intervention: Barotrauma
Number of subjects: 200
Study 36670050 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittently scanned continuous glucose monitoring (isCGM)
Number of subjects: 104
Study 36670050 — intervention group
Group type: COMPARATOR
Intervention: Blood glucose monitoring (BGM)
Number of subjects: 104
Study 36670100 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 vaccination in patients treated with immunotherapy (IO)
Number of subjects: 51
Study 36670295 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological intervention consisting of three sessions conducted by a clinical psychologist
Number of subjects: 30
Study 36670295 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 30
Study 36670365 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBO)
Number of subjects: 20
Study 36670376 — intervention group
Group type: EXPERIMENTAL
Intervention: Behaviourally-informed invitation letter
Number of subjects: 21876
Study 36670376 — intervention group
Group type: COMPARATOR
Intervention: Standard letter with no reminder
Number of subjects: 21876
Study 36670376 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural letter with no reminder
Number of subjects: 21876
Study 36670376 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard letter with reminder
Number of subjects: 21876
Study 36670376 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural letter with reminder
Number of subjects: 21876
Study 36670376 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminder SMS or email
Number of subjects: 21876
Study 36670384 — intervention group
Group type: EXPERIMENTAL
Intervention: Education to keep the abdomen relaxed during Pilates exercises
Number of subjects: 152
Study 36670384 — intervention group
Group type: COMPARATOR
Intervention: Guidance on the specific activation of the center of strength (control group)
Number of subjects: 152
Study 36670441 — intervention group
Group type: EXPERIMENTAL
Intervention: DAPT for 36 months
Number of subjects: 2106
Study 36670441 — intervention group
Group type: COMPARATOR
Intervention: DAPT for 12 months
Number of subjects: 2106
Study 36670471 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced von Willebrand factor (1:1 vWF and FVIII) in addition to platelet transfusion
Number of subjects: 120
Study 36670471 — intervention group
Group type: COMPARATOR
Intervention: Platelet transfusion alone
Number of subjects: 120
Study 36670495 — intervention group
Group type: EXPERIMENTAL
Intervention: PHYCOCARE® (phycocyanin) during oxaliplatin-based chemotherapy
Number of subjects: 110
Study 36670495 — intervention group
Group type: COMPARATOR
Intervention: Placebo during oxaliplatin-based chemotherapy
Number of subjects: 110
Study 36670877 — intervention group
Group type: EXPERIMENTAL
Intervention: YPL-001
Number of subjects: 0
Study 36671553 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel hominid-specific IAPP isoforms
Number of subjects: 0
Study 36671553 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 36672386 — intervention group
Group type: EXPERIMENTAL
Intervention: Next-Generation Sequencing (NGS) implementation for AML diagnosis
Number of subjects: 2668
Study 36672386 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized NGS studies
Number of subjects: 2668
Study 36672947 — intervention group
Group type: EXPERIMENTAL
Intervention: MedDiet + MAB juice
Number of subjects: 24
Study 36672947 — intervention group
Group type: COMPARATOR
Intervention: MedDiet
Number of subjects: 24
Study 36673773 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Family Psychoeducation (MBFPE)
Number of subjects: 65
Study 36673773 — intervention group
Group type: COMPARATOR
Intervention: Ordinary Family Psychoeducation (FPE)
Number of subjects: 65
Study 36673939 — intervention group
Group type: EXPERIMENTAL
Intervention: Sophrology/NLP intervention
Number of subjects: 0
Study 36673939 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 36673992 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial intervention engagement (number of completed counseling sessions)
Number of subjects: 372
Study 36673992 — intervention group
Group type: EXPERIMENTAL
Intervention: White participants
Number of subjects: 372
Study 36673992 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy (NRT) use during the initial intervention
Number of subjects: 372
Study 36674120 — intervention group
Group type: EXPERIMENTAL
Intervention: Myofascial release with Findings-Oriented Orthopedic Manual Therapy (OMT) combined with Foam Roller (FR)
Number of subjects: 29
Study 36674120 — intervention group
Group type: COMPARATOR
Intervention: Foam Roller (FR) alone
Number of subjects: 29
Study 36674197 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprioceptive Neuromuscular Facilitation stretching (PNF)
Number of subjects: 80
Study 36674197 — intervention group
Group type: COMPARATOR
Intervention: Foam Rolling (FR)
Number of subjects: 80
Study 36675009 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary habits of active Crohn's disease patients
Number of subjects: 54
Study 36675009 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood levels in active Crohn's disease patients
Number of subjects: 54
Study 36675633 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with heart disease
Number of subjects: 7014
Study 36675633 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 vaccine
Number of subjects: 7014
Study 36675633 — intervention group
Group type: COMPARATOR
Intervention: Patients without cardiovascular disease
Number of subjects: 7014
Study 36678170 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg/day ISF Supplement
Number of subjects: 118
Study 36678170 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg/day ISF Diet
Number of subjects: 118
Study 36678170 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 118
Study 36678170 — intervention group
Group type: EXPERIMENTAL
Intervention: ISF Supplement among women enrolled within 5 years of menopause
Number of subjects: 118
Study 36678191 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg of EGCG daily alone
Number of subjects: 39
Study 36678191 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg of EGCG daily with clomiphene citrate 100 mg for 5 days
Number of subjects: 39
Study 36678191 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg of EGCG daily with Letrozole 5 mg for 5 days
Number of subjects: 39
Study 36678312 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone exposure
Number of subjects: 0
Study 36678312 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A status
Number of subjects: 0
Study 36678638 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin at 35 mg/kg (HR35ZE group)
Number of subjects: 134
Study 36678638 — intervention group
Group type: COMPARATOR
Intervention: Rifampicin at 10 mg/kg (historical HR10ZE group)
Number of subjects: 134
Study 36678659 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy applied once a week for four sessions with orabase cream
Number of subjects: 60
Study 36678659 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-power laser application with orabase cream
Number of subjects: 60
Study 36678659 — intervention group
Group type: COMPARATOR
Intervention: Inactive laser with triamcinolone acetonide 0.1%
Number of subjects: 60
Study 36679862 — intervention group
Group type: EXPERIMENTAL
Intervention: MVC-COV1901 vaccine (two doses, 28 days apart)
Number of subjects: 57
Study 36680319 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 36680419 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalbuphine extended release (ER) 108 mg BID
Number of subjects: 71
Study 36680419 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalbuphine extended release (ER) 162 mg BID
Number of subjects: 71
Study 36680419 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 36680576 — intervention group
Group type: EXPERIMENTAL
Intervention: SWL with Virtual Reality (VR)
Number of subjects: 166
Study 36680576 — intervention group
Group type: COMPARATOR
Intervention: SWL without Virtual Reality (VR)
Number of subjects: 166
Study 36680581 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulvestrant 500 mg + Palbociclib
Number of subjects: 354
Study 36680581 — intervention group
Group type: COMPARATOR
Intervention: Fulvestrant 500 mg + Placebo
Number of subjects: 354
Study 36680617 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-expanding valve (n=103)
Number of subjects: 203
Study 36680617 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon-expanding valve (n=100)
Number of subjects: 203
Study 36680617 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrophysiologic study (EPS) of atrioventricular conduction
Number of subjects: 203
Study 36680620 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofol-0.3 mg/kg
Number of subjects: 109